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Hypertension, oedema, or serious potassium loss has been reported in up to 50 % of patients receiving carbenoxolone sodium, 300 mg. daily, for the treatment of gastric ulcer (Doll, Hill, Hutton, and Underwood, 1962; Doll, Hill, and Hutton, 1965; Turpie and Thomson, 1965; Horwich and Galloway, 1965) . According to Turpie and Thomson's observations on 10 patients, these side effects can also occur with a dosage of 150 mg. daily for four weeks, and they concluded that carbenoxolone sodium should only be used when close clinical supervision and biochemical facilities are available.
This paper reports the effects on 50 out-patients treated with carbenoxolone sodium, 150 mg. daily for six weeks, as part of a long-term prospective study of the medical management of gastric ulcers based on this drug.
METHOD
All patients were included who presented with an apparently benign gastric ulcer demonstrable radiologically, in the absence of intractable haemorrhage, pyloric obstruction, severe hypertension, or heart failure. The average age of the subjects was 49 years, and six of them were over 65. The length of history ranged from three weeks to 25 years with a mean of four years. Nine subjects had hypertension, with a resting diastolic blood pressure of 95 to 105 mm. Hg.
Carbenoxolone sodium was administered as 50 mg. tablets three times a day after meals for six weeks, commencing within two weeks of a barium meal. Clinical state, body weight, and blood pressure were recorded at intervals of three weeks, and a barium meal was repeated after six weeks. If an ulcer was still visible, the treatment was continued for another six weeks. Serum electrolytes and urea were estimated on the last day of treatment in 32 patients, and before treatment in 18 of these. One patient was withdrawn because he proved to have a gastric carcinoma.
The cases were treated as out-patients, and were not confined to bed, normal work and activities being permitted as soon as they were free of serious symptoms. Table I ; four are excluded from this analysis because they had periods of bed rest, two others defaulted from a repeat radiograph (all six were free of symptoms), and one died (see below).
In six weeks 13 ulcers (430 %) were radiologically healed and another four (13 %) almost healed, and the average reduction in profile area of the ulcer was 61 %. Eight patients (27 %) had persisting symptoms.
Three of the latter (cases 11, 21, and 38), whose histories were longer than five years, were subjected to gastrectomy. Nine patients with a persisting niche received a further course of treatment, as did case 15 with persisting symptoms. After 12 weeks a niche was still demonstrable in seven cases, and one other (case 4) had symptoms and later showed radiological recurrence. Case 35, with eight years' history, was referred for surgery with severe symptoms at 10 weeks. Thus 18 (60%) were 'healed' and symptomfree in 12 weeks.
SIDE EFFECTS
Apart from the group of 37 patients described above, the regime was applied to seven patients with gastric ulcers distal to the angulus, with niches not readily measurable, and to six patients with combined
Side effects of carbenoxolone sodium: a study of ambulant therapy ofgastric ulcer 1 inference to any patients with chronic cardiac, renal, or hepatic disease, and it should not be given in conjunction with steroid therapy. In other subjects no ill effects appear to accompany its use over a period of six weeks, nor, in a limited series, over a period of 12 weeks. In particular no serious loss of potassium was found. On this dose schedule it appears to be as safe a drug as many others which are freely prescribed in general practice. It remains to be proved that carbenoxolone sodium in this dosage is of value in the treatment of gastric ulcer. The results after six weeks of ambulant treatment in this series, however, are similar to those of Doll et al. (1962 Doll et al. ( , 1965 who used twice the dosage for four weeks, and compare favourably with their two control series on inert tablets, radiographed after five weeks (Table lII) . The mean serum potassium level in 32 subjects on the last day of treatment was 41 mEq./l., and the mean fall in 18 subjects was 0.3 mEq./l Carbenoxolone sodium in this dosage is a safe drug in normotensive subjects in the absence of chronic cardiac, renal, or hepatic disease. Its therapeutic value in this dosage had yet to be proved, but the short-term effect on the ulcer niche in this. series is encouraging. 
